A judge's decision to allow 13 plaintiff's witnesses to testify as experts may have swayed GSK plc to announce a settlement in litigation in California state court alleging the firm’s ranitidine-containing Zantac caused the plainitff's bladder cancer and the firm failed to warn of the cancer risk.
The UK pharma, which doesn’t market Zantac OTC in the US but developed and previously manufactured and marketed the heartburn remedy as an Rx product, said it reached a confidential settlement with plaintiff
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?